{"drugs":["Avonex","Avonex Pen","Interferon Beta-1a","Rebif","Rebif Rebidose","Rebif Rebidose Titration Pack"],"mono":{"0":{"id":"923609-s-0","title":"Generic Names","mono":"Interferon Beta-1a"},"1":{"id":"923609-s-1","title":"Dosing and Indications","sub":[{"id":"923609-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Multiple sclerosis, Relapsing forms:<\/b> Avonex(R), 30 mcg IM once weekly, OR, initial, 7.5 mcg IM on week 1, then increase dose by 7.5 mcg each week until 30 mcg once weekly is reached; pretreatment with analgesics or antipyretics on injection days may decrease flu-like symptoms<\/li><li><b>Multiple sclerosis, Relapsing forms:<\/b> Rebif(R) titration to 22 mcg dose: initial, 4.4 mcg SUBQ 3 times\/week for weeks 1 and 2; increase to 11 mcg SUBQ 3 times\/week for weeks 3 and 4, then 22 mcg SUBQ 3 times\/week<\/li><li><b>Multiple sclerosis, Relapsing forms:<\/b> Rebif(R) titration to 44 mcg dose: initial, 8.8 mcg SUBQ 3 times\/week for weeks 1 and 2; increase to 22 mcg SUBQ 3 times\/week for weeks 3 and 4, then 44 mcg SUBQ 3 times\/week<\/li><\/ul>"},{"id":"923609-s-1-5","title":"Pediatric Dosing","mono":"safety and effectiveness have not been established in pediatric patients under 18 years of age "},{"id":"923609-s-1-6","title":"Dose Adjustments","mono":"<b>geriatric:<\/b> initiate with lower dose, use caution "},{"id":"923609-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Multiple sclerosis, Relapsing forms<br\/><b>Non-FDA Labeled Indications<\/b><br\/>Multiple sclerosis, Clinically Isolated Syndrome<br\/>"}]},"3":{"id":"923609-s-3","title":"Contraindications\/Warnings","sub":[{"id":"923609-s-3-9","title":"Contraindications","mono":"<ul><li>hypersensitivity to human albumin (Avonex(R) lyophilized powder vial and Rebif(R) prefilled syringes)<\/li><li>hypersensitivity to natural or recombinant interferon beta or to any other component of the formulation<\/li><\/ul>"},{"id":"923609-s-3-10","title":"Precautions","mono":"<ul><li>Cardiovascular<\/li><li>-- cardiac toxicity, including congestive heart failure and cardiomyopathy with or without congestive heart failure, have been reported in patients with no predisposition to these events<\/li><li>-- worsening of preexisting congestive heart failure may occur during initiation and continued treatment; monitoring recommended<\/li><li>Dermatologic<\/li><li>-- injection site reactions, including necrosis, have been reported with subQ administration, sometimes long after therapy initiation; monitoring of self-injection recommended<\/li><li>Endocrine<\/li><li>-- new or worsening thyroid dysfunction has been reported; monitoring recommended<\/li><li>Hematologic<\/li><li>-- decreased peripheral blood counts, including pancytopenia, have been reported; monitoring recommended<\/li><li>Hepatic<\/li><li>-- active or past significant liver disease or dysfunction, or alcohol abuse; dosage reduction may be needed<\/li><li>-- hepatic injury, including hepatic failure and asymptomatic elevation of hepatic transaminases, has been reported; monitoring recommended; dosage reduction or discontinuation of therapy may be needed<\/li><li>Immunologic<\/li><li>-- anaphylaxis  and allergic reactions, some cases after prolonged use, have been reported<\/li><li>-- autoimmune disorders (eg, idiopathic thrombocytopenia, hyper- and hypothyroidism, autoimmune hepatitis) have been reported; monitoring recommended and therapy discontinuation should be considered<\/li><li>-- latex sensitivity; syringe tip cap contains latex<\/li><li>Neurologic<\/li><li>-- seizures have been reported, sometimes in patients with no prior history; use caution in patients with preexisting seizure disorders<\/li><li>Psychiatric<\/li><li>-- depression, suicidal ideation and suicide, or new development or worsening of psychiatric disorders, including psychosis, have been reported; consider discontinuation if depression  or other severe psychiatric symptoms  develop<\/li><\/ul>"},{"id":"923609-s-3-11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>D (AUS)<\/li><\/ul>"},{"id":"923609-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk is minimal.<br\/>"}]},"4":{"id":"923609-s-4","title":"Drug Interactions","sub":{"0":{"id":"923609-s-4-13","title":"Contraindicated","mono":"<ul>Rotavirus Vaccine, Live (established)<\/ul>"},"2":{"id":"923609-s-4-15","title":"Moderate","mono":"<ul>Zidovudine (probable)<\/ul>"}}},"5":{"id":"923609-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Injection site reaction (3% to 92%)<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (8% to 22%), Nausea (23%)<\/li><li><b>Hepatic:<\/b>Abnormal liver function (4% to 9%), ALT\/SGPT level raised (20% to 27%), AST\/SGOT level raised (10% to 17%), Hyperbilirubinemia (2% to 3%)<\/li><li><b>Immunologic:<\/b>Antibody development (5% to 31%), Autoimmune hepatitis, Lymphadenopathy (11% to 12%)<\/li><li><b>Musculoskeletal:<\/b>Backache (23% to 25%), Musculoskeletal pain (10% to 15%), Myalgia (25% to 29%)<\/li><li><b>Neurologic:<\/b>Asthenia (24%), Dizziness (14%), Headache (58% to 70%)<\/li><li><b>Ophthalmic:<\/b>Abnormal vision (7% to 13%)<\/li><li><b>Psychiatric:<\/b>Depression (18%)<\/li><li><b>Renal:<\/b>Urinary tract infectious disease (17%)<\/li><li><b>Respiratory:<\/b>Sinusitis (14%), Upper respiratory infection (14%)<\/li><li><b>Other:<\/b>Fatigue (33% to 41%), Fever (20% to 28%), Influenza-like symptoms (49% to 59%), Pain (23%), Shivering (19%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Cardiomyopathy, Congestive heart failure<\/li><li><b>Dermatologic:<\/b>Injection site necrosis (1% to 3%)<\/li><li><b>Hematologic:<\/b>Anemia (3% to 5%), Leukopenia (up to 36%), Pancytopenia, Thrombocytopenia (2% to 8%)<\/li><li><b>Hepatic:<\/b>Hepatotoxicity, Injury of liver (rare), Liver failure (rare)<\/li><li><b>Immunologic:<\/b>Anaphylaxis (rare), Hypersensitivity reaction, Systemic lupus erythematosus<\/li><li><b>Neurologic:<\/b>Seizure (4% to 5%)<\/li><li><b>Ophthalmic:<\/b>Retinal vascular disorder<\/li><li><b>Psychiatric:<\/b>Suicidal thoughts<\/li><\/ul>"},"6":{"id":"923609-s-6","title":"Drug Name Info","sub":{"0":{"id":"923609-s-6-17","title":"US Trade Names","mono":"<ul><li>Avonex<\/li><li>Rebif<\/li><li>Avonex Pen<\/li><li>Rebif Rebidose<\/li><li>Rebif Rebidose Titration Pack<\/li><\/ul>"},"2":{"id":"923609-s-6-19","title":"Class","mono":"<ul><li>Immunological Agent<\/li><li>Interferon, Beta (class)<\/li><\/ul>"},"3":{"id":"923609-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"923609-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"923609-s-7","title":"Mechanism Of Action","mono":"Interferon beta-1a is a purified glycoprotein which has an identical amino acid sequence as natural fibroblast-derived human interferon beta. Interferons are cytokines that mediate antiviral, antiproliferative, and immunomodulatory activities. The mechanism of action of interferon beta-1a in the treatment of multiple sclerosis is unknown.<br\/>"},"8":{"id":"923609-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"923609-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, IM (Avonex(R)): 15 hours<\/li><li>Tmax, subQ (Rebif(R)): 16 hours<\/li><\/ul>"},"3":{"id":"923609-s-8-26","title":"Excretion","mono":"Total body clearance: 33 to 55 L\/hr <br\/>"},"4":{"id":"923609-s-8-27","title":"Elimination Half Life","mono":"<ul><li>Avonex(R) IM: 19 hours<\/li><li>Rebif(R) SubQ: 69 hours<\/li><\/ul>"}}},"9":{"id":"923609-s-9","title":"Administration","mono":"<ul><li><b>Intramuscular<\/b><br\/><ul><li>Avonex(R) should be given via IM administration<\/li><li>vial, prefilled syringe, and prefilled autoinjector are all single-use only<\/li><li>reconstitute vials with sterile water for injection to concentration of 30 mcg\/mL<\/li><li>use reconstituted vials immediately or within 6 hours if refrigerated at 2 to 8 degrees C (36 to 46 degrees F)<\/li><li>(prefilled syringe, prefilled autoinjector) warm to room temperature for 30 minutes; do not use external heat sources to warm (eg, hot water)<\/li><li>(prefilled syringe, prefilled autoinjector) once removed from the refrigerator, may store at 77 degrees F (25 degrees C) or lower and administer within 7 days<\/li><li>rotate injection sites; do not inject in areas where skin is irritated, reddened, bruised, infected, or scarred in any way<\/li><li>check injection site after 2 hours for signs of redness, swelling, or tenderness<\/li><\/ul><\/li><li><b>Subcutaneous<\/b><br\/><ul><li>Rebif(R) should be given via subQ administration.<\/li><li>may be warmed at room temperature for 30 minutes prior to administration<\/li><li>allow at least 48 hours between injections; give at same time of day, preferably late afternoon or evening, on the same 3 days each week; rotate injection sites<\/li><li>use only prefilled syringes for titration to 22 mcg; prefilled syringes or autoinjector may be used for titration to 44 mcg<\/li><li>single use only; discard unused portion use<\/li><\/ul><\/li><\/ul>"},"10":{"id":"923609-s-10","title":"Monitoring","mono":"<ul><li>delay in the progression of disability and a decrease in the frequency of exacerbations are indicative of a therapeutic response<\/li><li>changes in MRI studies may indicate improvement<\/li><li>blood chemistries; during therapy<\/li><li>CBC with differential  1, 3, and 6 months after initiation of therapy, then periodically; more frequent monitoring may be required for patients with myelosuppression<\/li><li>liver function tests  1, 3, and 6 months after initiation of therapy, then periodically<\/li><li>thyroid function tests; every 6 months in patients with a history of thyroid dysfunction or as clinically indicated<\/li><li>cardiac disease worsening; during initiation and continued treatment, in patients with preexisting congestive heart failure<\/li><li>signs and symptoms of decreased blood counts and hepatic injury<\/li><li>seizures, especially in patients with preexisting disorders<\/li><li>self-injection technique periodically, especially if injection-site necrosis has previously occurred<\/li><\/ul>"},"11":{"id":"923609-s-11","title":"How Supplied","mono":"<ul><li><b>Avonex<\/b><br\/><ul><li>Intramuscular Kit: 30 MCG<\/li><li>  Kit: 30 MCG\/0.5 ML<\/li><\/ul><\/li><li><b>Avonex Pen<\/b><br\/>  Kit: 30 MCG\/0.5 ML<br\/><\/li><li><b>Rebif Rebidose<\/b><br\/>Subcutaneous Solution: 22 MCG\/0.5 ML, 44 MCG\/0.5 ML<br\/><\/li><li><b>Rebif<\/b><br\/>Subcutaneous Solution: 22 MCG\/0.5 ML, 44 MCG\/0.5 ML<br\/><\/li><\/ul>"},"12":{"id":"923609-s-12","title":"Toxicology","sub":[{"id":"923609-s-12-31","title":"Clinical Effects","mono":"<b>INTERFERONS<\/b><br\/>OVERDOSE: Data are limited. Shivers, myalgias, low grade fever and tachycardia have been reported. ADVERSE EFFECTS: \"flu-like\" symptoms (fever, chills, tachycardia, headache, malaise, and myalgias), hypotension, seizures, headache, lethargy, fatigue, elevated liver enzymes, leukopenia, & renal insufficiency; dysrhythmias in patients with underlying heart disease. Vomiting, diarrhea, hyperkalemia, hypocalcemia occur at high doses.<br\/>"},{"id":"923609-s-12-32","title":"Treatment","mono":"<b>INTERFERONS<\/b><br\/><ul><li>Decontamination: Not indicated; broken down in the gut on oral ingestion.<\/li><li>Influenza-like illness: Treat with acetaminophen or non-steroidal anti-inflammatory agents<\/li><li>Hypotensive episode: Transient, usually requires no treatment;  0.9% NaCl 10-20 ml\/kg, dopamine, epinephrine if persistent<\/li><li>Monitoring of patient: CBC, hepatic &amp; renal function; ECG, calcium, potassium if severe overdose.<\/li><\/ul>"},{"id":"923609-s-12-33","title":"Range of Toxicity","mono":"<b>INTERFERONS<\/b><br\/>Single doses greater than 100-200 million units associated with toxicity. <br\/>"}]},"13":{"id":"923609-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to report depression, suicidal ideation, or unusual changes in behavior.<\/li><li>Instruct patient to report symptoms of infection or hepatotoxicity.<\/li><li>Counsel patient to report symptoms of congestive heart failure or cardiomyopathy.<\/li><li>Side effects may include headache, flu-like symptoms, fever, myalgia, fatigue, asthenia, or injection site reactions.<\/li><li>Warn patient to report seizures.<\/li><li>If self-administered, instruct patient on proper technique for injection.<\/li><li>Avonex(R): Tell patient with latex sensitivity that the prefilled syringe tip cap contains natural rubber latex.<\/li><li>Rebif(R): Advise patient to give injections at the same time of day (late afternoon or evening), on the same 3 days each week, and at least 48 hours apart.<\/li><\/ul>"}}}